BioWorld Asia

May 28, 2008

New Target Raises Hopes for Future Cancer Vaccines

Amsterdam Molecular Signs CRADA for Gene Therapy

BioAlliance Buys Rights to NovaDel's Ondansetron

Myriad Gets $100M Up Front in European Deal for Flurizan

EU Biosimilar Debate Moves to Use in Clinical Practice

LONDON - With the first generic biologics reaching the market in Europe, the focus has shifted from arguments about how to approve them, to how the products should be used in clinical practice. (BioWorld International) Read More

Daiichi Sankyo Paying $235M For U3's Oncology Pipeline

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 12, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Science in 2025: the best of the rest

BioWorld Science

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...